Fin Cascade
Get Android appGet iOS app

Prices as of 8 Oct 2026 close · Not investment advice

QMS Medical Allied Services Limited

NSE: QMSMEDIMedical Equipment & SuppliesTrade-to-trade true

Share price

₹192.52

-4.21% close of 8 Oct 2026

Market cap ₹366 CrP/E 34.0

Business score

How strong the business is, in one number. The parts behind it are in Pro.

59

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹366 Cr

P/E ratio

34.0

P/B ratio

3.6

ROCE

12.9%

ROE

10.4%

Dividend yield

0.3%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 8 Oct 2026 close52-week high ₹216.7952-week low ₹72.00

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales grew 6.4% over the past year, and 16.8% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales improved from 14.0% to 15.4% over the last three years.

Whether it grew faster than its sector

It grew 16.8% a year against a sector median of 13.1% — 3.7 percentage points faster.

Room to re-rate, or risk of de-rating

Too little price history yet to compare it with its own past.

Whether growth justifies the valuation

It has no steady three-year profit record yet, so growth cannot be weighed against the price.

Profit growthPrice per ₹1 profitPer 1% growth
QMS Medical Allied Services Limited — this one—34.0×—
Molbio Diagnostics Limited—97.4×—
Poly Medicure Limited15%/yr51.2×₹3.4
Fischer Medical Ventures Limited831%/yr84.9×—
Tarsons Products Limited—150.2×—
Laxmi Dental Limited124%/yr30.4×—

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Medical Equipment & Supplies), it ranks 3 of 8 on returns, 2 of 6 on growth, 5 of 8 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

A narrow advantage: it earns 12.9% on capital, ahead of 63% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

Yes — Over the 3 years of cash statements on file it made ₹39 crore of cash from the business and spent ₹3 crore on plant and equipment, with ₹36 crore to spare; it still raised ₹28 crore mostly borrowed — borrowings rose from ₹35 crore to ₹74 crore.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

7 of 8 checks clear · 88%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Revenue grew 22% and margins improved to 14.6%, still short of the 18% promised for the full year.

Announced 14 Aug 2026 · Consolidated · Unaudited

Revenue

₹57 Cr

Revenue vs last year

+22.3%

Revenue vs last quarter

+28.0%

Net profit

₹4 Cr

Profit vs last year

+25.6%

Profit vs last quarter

+95.9%

Net margin

7.0%

EPS

₹2.05

Earnings call transcript · 17 Aug 2026

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹366 Cr
Prev close
₹192.52
52w High
₹217
52w Low
₹68.9
Enterprise value
₹433 Cr
Beta
0.6
Price CAGR 1y
88.0%
Price CAGR 3y
14.0%
Price CAGR 5y
—
Price CAGR 10y
—

Ratios

Return on assets
5.6%
PEG ratio
—
P/E ratio
34.0
P/B ratio
3.6
EV / EBITDA
15.5
Industry P/E
59.5
ROCE
12.9%
ROCE 5y average
15.0%
ROE
10.4%
Debt / Equity
0.7
Interest coverage
3.3
Dividend yield
0.3%
ROE 3y average
12.0%
ROE last year
10.0%

Annual P&L

Annual revenue
₹173 Cr
Annual profit
₹12 Cr
Operating margin
15.0%
Net profit margin
6.9%
EBITDA margin
15.0%
Sales growth 3y
—
Sales growth 5y
—
Profit growth 3y
—
Profit growth 5y
—
EPS
₹5.2
Sales growth TTM
6.0%
Profit growth TTM
-15.0%
Dividend payout
95.0%

Quarter P&L

Sales latest quarter
₹57 Cr
Profit latest quarter
₹4 Cr
YoY quarterly sales growth
22.3%
YoY quarterly profit growth
25.3%
OPM latest quarter
14.6%

Balance Sheet

Book Value
₹54.7
Face Value
₹10.0
Total debt
₹74 Cr
Total cash
₹1 Cr
Borrowings
₹74 Cr
Reserves / Equity
4.5

Cash Flow

Operating cash flow
₹19 Cr
Free cash flow
₹19 Cr
FCF yield
3.3%
Net cash flow
₹0 Cr

Shareholding

Promoter holding
68.1%
FII holding
0.0%
DII holding
1.6%
Public holding
30.3%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Molbio Diagnosti1,514.8580.417,4570.0056.6522.3399.4319.018.0
Poly Medicure1,592.7050.516,1440.2285.3-7.6525.430.312.5
Fischer Medical31.6190.22,2090.153.8-22.081.9249.511.4
Tarsons Products332.60149.51,7700.00-1.4-180.9110.220.74.6
Q-Line Biotech659.0527.11,5370.0034.4147.3197.9-8.622.4
Laxmi Dental190.7530.21,0500.0010.322.874.713.915.1
Hemant Surgical631.9554.39190.0012.8159.2166.7189.218.9
QMS Medical195.5035.23780.264.024.656.922.312.9
Median331.0536.36580.004.219.874.721.515.1

Competes with: Fischer Medical Ventures Limited, Laxmi Dental Limited, Molbio Diagnostics Limited, Poly Medicure Limited, Tarsons Products Limited

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales31262935323744454745374457
Expenses30283037384038313949
Material Cost00
Change in Inventories-1.89-3.88
Purchases of Stock-in-Trade2830
Employee Cost3.3311
Other Expenses1111
Operating Profit4.843.957.246.946.376.546.926.755.928.31
OPM %10181714121916141415181315
Other Income0.150.110.330.191.090.320.220.300.220.42
Exceptional items (within Other Income)0
Interest0.810.991.071.311.411.441.361.752.081.71
Depreciation0.880.880.840.861.360.930.941.021.391.47
Profit before tax3.302.195.664.964.694.494.844.282.675.55
Tax %26302530233026262929
Net Profit2.441.544.233.473.603.163.583.171.883.96
EPS in Rs1.260.801.781.511.731.521.611.240.821.89
Diluted EPS in Rs3.511.643.321.242.112.05

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2024Mar 2025Mar 2026TTM
Sales122156173183
Expenses104130147155
Operating Profit18252628
OPM %15161515
Other Income0211
Interest34.6477
Depreciation3.443.8345
Profit before tax12191617
Tax %262727
Net Profit9.00141213
EPS in Rs4.666.265.245.56
Diluted EPS in Rs6.775.40
Dividend Payout %-07495

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
—
5 years
—
3 years
—
TTM
6%

Compounded profit growth

10 years
—
5 years
—
3 years
—
TTM
-15%

Stock price CAGR

10 years
—
5 years
—
3 years
14%
1 year
88%

Return on equity

10 years
—
5 years
—
3 years
12%
Last year
10%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2024Mar 2025Mar 2026
Equity Capital181819
Reserves617285
Borrowings356074
Other Liabilities224034
Total Liabilities135190213
Fixed Assets245255
CWIP233
Investments235
Other Assets108131150
Total Assets135190213

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2024Mar 2025Mar 2026
Cash from Operating Activity11919
Cash from Investing Activity-3-45-20
Cash from Financing Activity0271
Net Cash Flow-110
Free Cash Flow11619

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2024Mar 2025Mar 2026
Debtor Days124136142
Inventory Days172176181
Days Payable907673
Cash Conversion Cycle205236251
Working Capital Days14810093
ROCE %1713

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026
Line itemDec 2022Mar 2023Sep 2023Mar 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026Jun 2026
Promoters74747474747474686868
FIIs0.711.211.020.010.010.010.010.0100
DIIs00000001.601.591.59
Public26252526262626303030
No. of Shareholders9251,0431,2131,5861,6951,5191,4891,5641,4991,554

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year +80.8% (₹106.50 → ₹192.52)Brick size ₹10.34 (fixed)Bricks 16
₹100₹150₹193Jan '26Aug '26
Price moved up one brickPrice moved down one brickLast close ₹192.52 on 8 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2025-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash

67.54inr_cr

2026-03-31

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

News

News and filings about QMS Medical Allied Services Limited. Open one to see why it matters.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Buys drug ingredients from

  • 3M
  • Heine (Heine Optotechnik)
  • Rossmax

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Medical Equipment & Supplies
Classification
Healthcare › Medical Equipment & Supplies
ISIN
INE0FMW01018

News impact

Big market events that reach QMS Medical Allied Services Limited, and how the effect spreads.

No recent market events reach this company.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

23 Sep 2026unspecified₹0.5

Splits, bonuses & buybacks

  • daily-prices repair: 12 rows from NSE's archive (replace 5, delete 2, insert 5), 2022-11-16..2026-05-28 (docs/flat_day_repair.md)1× · 16 Nov 2022

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.